Why does it carry a boxed warning?

Pegvaliase can cause anaphylaxis, a potentially life-threatening allergic reaction, at any point during treatment. That is why it carries an FDA boxed warning and is only dispensed through a restricted REMS program.

What do REMS and epinephrine have to do with it?

REMS (Risk Evaluation and Mitigation Strategy) is a restricted-access program. Patients must be prescribed auto-injectable epinephrine and trained to use it before starting, so anaphylaxis can be treated immediately.

It is a subcutaneous injection started at a low dose and titrated up slowly over weeks under medical supervision, with maintenance individualized to a person's phenylalanine response.

Does it replace the PKU diet automatically?

Not necessarily. Effects on diet are individualized and managed by a metabolic team; any dietary changes are made under specialist guidance, not self-directed.

FDA-approved medicineaka Palynziq, pegvaliase-pqpz

Pegvaliase — Complete Research Guide (2026)

Last updated 2026-07-31

TL;DR

A PEGylated phenylalanine ammonia-lyase enzyme, FDA-approved (2018, Palynziq) to lower blood phenylalanine in adults with phenylketonuria; boxed warning for anaphylaxis.

What is Pegvaliase?

Pegvaliase (brand name Palynziq) is a PEGylated recombinant Anabaena variabilis phenylalanine ammonia-lyase enzyme administered by subcutaneous injection.

It is FDA-approved (2018) and EMA-approved as an enzyme-substitution therapy for adults with phenylketonuria (PKU) whose blood phenylalanine remains above 600 micromol/L on existing management.

Evidence is high-quality: approval rests on the randomized, controlled phase 3 PRISM development program in adults.

How does Pegvaliase work?

Phenylalanine ammonia-lyase converts excess phenylalanine into trans-cinnamic acid and ammonia, providing a phenylalanine-hydroxylase-independent route to lower blood phenylalanine.

PEGylation extends its half-life and is intended to reduce immunogenicity, though anti-drug antibody responses still occur and drive its safety profile.

What does the research say about Pegvaliase?

In the phase 3 PRISM program, pegvaliase produced substantial, sustained reductions in blood phenylalanine toward or into the therapeutic range in adults with PKU. ^[1]
A pivotal double-blind randomized discontinuation trial (PRISM-2) confirmed that continued pegvaliase maintained lower blood phenylalanine versus placebo withdrawal. ^[2]
Long-term final phase 3 results showed durable phenylalanine control with continued treatment over multiple years. ^[4]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM) — Thomas J et al., Molecular Genetics and Metabolism 2018. (Phase 3 clinical trial program)
[2] Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial — Harding CO et al., Molecular Genetics and Metabolism 2018. (Randomized double-blind discontinuation trial (PRISM-2))
[3] Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials — Gupta S et al., EBioMedicine 2018. (Immunogenicity analysis of phase 3 trials)
[4] Pegvaliase for the treatment of phenylketonuria: Final results of a long-term phase 3 clinical trial program — Harding CO et al., Molecular Genetics and Metabolism Reports 2024. (Long-term phase 3 follow-up)
[5] Pegvaliase: First Global Approval — Markham A et al., BioDrugs 2018. (Regulatory/drug review)
[6] Long-Term Safety and Efficacy of Pegvaliase in Japanese Adults With Phenylketonuria: Final Results of a Phase III Trial — Nakajima Y et al., JIMD Reports 2026. (Phase 3 trial)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

This is context only and not medical advice: in trials pegvaliase was given by subcutaneous injection with a gradual induction/titration schedule (starting low and increasing over weeks) to reduce reaction risk, with maintenance individualized to phenylalanine response.

Dosing is initiated under medical supervision with observation because of the anaphylaxis risk and REMS requirements.

Side effects & safety profile

Pegvaliase carries an FDA boxed warning for anaphylaxis, which can occur at any time during treatment.

Because of this risk, it is available only through a restricted REMS program, and patients must be prescribed and trained to carry auto-injectable epinephrine.

Other very common reactions include injection-site reactions, arthralgia, and a high rate of hypersensitivity reactions linked to the immune response against the enzyme.

Stacking & combinations

Pegvaliase is a prescription enzyme therapy managed under a metabolic clinic and REMS program, not a compound to be combined with unregulated peptides or supplements.

Finding Pegvaliase vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is approved for adults with phenylketonuria (PKU) to reduce blood phenylalanine when it stays above target on other management. It is not approved for children in most regions and is not a general-purpose peptide supplement.

References

[1] Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM) — Thomas J et al., Molecular Genetics and Metabolism 2018. PMID: 29653686. View sourceStudy: Phase 3 clinical trial programPegvaliase produced clinically meaningful, sustained reductions in blood phenylalanine in adults with PKU.
[2] Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial — Harding CO et al., Molecular Genetics and Metabolism 2018. PMID: 29628378. View sourceStudy: Randomized double-blind discontinuation trial (PRISM-2)Continued pegvaliase maintained significantly lower blood phenylalanine than placebo withdrawal.
[3] Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials — Gupta S et al., EBioMedicine 2018. PMID: 30366815. View sourceStudy: Immunogenicity analysis of phase 3 trialsAnti-drug immune responses were associated with hypersensitivity reactions, though efficacy was largely retained over time.
[4] Pegvaliase for the treatment of phenylketonuria: Final results of a long-term phase 3 clinical trial program — Harding CO et al., Molecular Genetics and Metabolism Reports 2024. PMID: 38694233. View sourceStudy: Long-term phase 3 follow-upLong-term treatment gave durable phenylalanine reductions with a safety profile consistent with earlier reports.
[5] Pegvaliase: First Global Approval — Markham A et al., BioDrugs 2018. PMID: 30022433. View sourceStudy: Regulatory/drug reviewSummarizes the development and first regulatory approval of pegvaliase for adult PKU.
[6] Long-Term Safety and Efficacy of Pegvaliase in Japanese Adults With Phenylketonuria: Final Results of a Phase III Trial — Nakajima Y et al., JIMD Reports 2026. PMID: 41971647. View sourceStudy: Phase 3 trialConfirmed sustained phenylalanine lowering with a consistent safety profile in Japanese adults.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.